A groundbreaking nanosized polymer developed by researchers in Tel Aviv [Israel], Israel has shown promise in treating colorectal cancer live metastases, offering hope for patients facing advanced stages of the disease. Published in the peer-reviewed Nano Today journal, the study conducted by researchers at Ben-Gurion University of the Negev revealed how this novel therapy selectively delivers chemotherapeutic drugs to specific blood vessels that feed tumors and metastases. Colorectal cancer (CRC), also known as bowel cancer, colon cancer or recta cancer, is a type of cancer that affects the colon. Or rectum. In 70% of advanced cases, the cancer metastasizes – or spreads – to the liver. Liver metastases are common with CRC because the liver receives blood directly from the intestines, giving cancer cells an easy path to spread.The Ben-Gurion research team led by Professor Ayelet David unveiled a nanosized polymer 2-5 nanometers in size. , This polymer equipped with a targeting peptide works effectively on the endothelial cells lining blood vessels that support tumor growth. By specifically binding to the adhesion molecule E-selectin, which is found specifically on the endothelial cells of the new blood vessels feeding the tumor, the polymer delivers the cytotoxic drugs directly to the cancer sites "Colon cancer is a very aggressive tumor. And spreads very quickly in the liver." Up to 25% of patients with CRC have liver metastases at the time of diagnosis," Professor David explained. "Available personalized treatments can improve survival and quality of life for many patients with metastatic disease, although cure is rare, recurrence "Our unique polymer demonstrates preclinical results for the treatment of advanced cancer that has spread to other locations in the body and typically cannot be cured or controlled by other therapies.Colorectal cancer live metastases are targeted through Israeli nanotherapy. Half of the mice treated with the polymer demonstrated complete remission. After a single dose therapy, metastases from the liver were effectively eliminated; moreover, the long-term survival rates of these mice were better than those treated with conventional chemotherapy drugs. Doubled compared to the rats treated. The researchers have licensed the technology to Israeli biomedical company Vaxil Biotherapeutics for further development.Vaxil is taking steps to start human trials (ANI/TPS)